Rotavirus Vaccine Workshop May Address Intussusception Biomarker Data
Executive Summary
A potential rotavirus vaccine-related intussusception biomarker could be a topic at a September workshop organized by the Centers for Disease Control & Prevention's National Vaccine Program Office and the National Vaccine Advisory Committee.
You may also be interested in...
GSK Rotavirus Vaccine Phase III Safety Trials Will Enroll 50,000 Children
GlaxoSmithKline will evaluate the rotavirus vaccine Rotarix in 50,000 children in Phase III safety trials set to begin at the end of 2001, Biologicals President Jean Stephenne told a London analysts conference Feb. 22.
Rotavirus Vaccine Phase III Trials May Require 60,000 - 100,000 Patients
Rotavirus vaccine Phase III studies may require between 60,000 and 100,000 patients to address rare adverse event risks, Thomas Fleming, PhD, University of Washington, said during the Vaccines & Related Biological Products Advisory Committee meeting May 11.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011